Removing the Age Restrictions for Rotavirus Vaccination: A Benefit-Risk Modeling Analysis

English version České info

Background:
To minimize potential risk of intussusception, the World Health Organization (WHO) recommended in 2009 that rotavirus immunization should be initiated by age 15 weeks and completed before 32 weeks. These restrictions could adversely impact vaccination coverage and thereby its health impact, particularly in developing countries where delays in vaccination often occur.

Methods and Findings:
We conducted a modeling study to estimate the number of rotavirus deaths prevented and the number of intussusception deaths caused by vaccination when administered on the restricted schedule versus an unrestricted schedule whereby rotavirus vaccine would be administered with DTP vaccine up to age 3 years. Countries were grouped on the basis of child mortality rates, using WHO data. Inputs were estimates of WHO rotavirus mortality by week of age from a recent study, intussusception mortality based on a literature review, predicted vaccination rates by week of age from USAID Demographic and Health Surveys, the United Nations Children's Fund (UNICEF) Multiple Indicator Cluster Surveys (MICS), and WHO-UNICEF 2010 country-specific coverage estimates, and published estimates of vaccine efficacy and vaccine-associated intussusception risk. On the basis of the error estimates and distributions for model inputs, we conducted 2,000 simulations to obtain median estimates of deaths averted and caused as well as the uncertainty ranges, defined as the 5th–95th percentile, to provide an indication of the uncertainty in the estimates.

We estimated that in low and low-middle income countries a restricted schedule would prevent 155,800 rotavirus deaths (5th–95th centiles, 83,300–217,700) while causing potentially 253 intussusception deaths (76–689). In contrast, vaccination without age restrictions would prevent 203,000 rotavirus deaths (102,000–281,500) while potentially causing 547 intussusception deaths (237–1,160). Thus, removing the age restrictions would avert an additional 47,200 rotavirus deaths (18,700–63,700) and cause an additional 294 (161–471) intussusception deaths, for an incremental benefit-risk ratio of 154 deaths averted for every death caused by vaccine. These extra deaths prevented under an unrestricted schedule reflect vaccination of an additional 21%–25% children, beyond the 63%–73% of the children who would be vaccinated under the restricted schedule. Importantly, these estimates err on the side of safety in that they assume high vaccine-associated risk of intussusception and do not account for potential herd immunity or non-fatal outcomes.

Conclusions:
Our analysis suggests that in low- and middle-income countries the additional lives saved by removing age restrictions for rotavirus vaccination would far outnumber the potential excess vaccine-associated intussusception deaths.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Removing the Age Restrictions for Rotavirus Vaccination: A Benefit-Risk Modeling Analysis. PLoS Med 9(10): e32767. doi:10.1371/journal.pmed.1001330
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001330

Souhrn

Zdroje

1. TateJE, BurtonAH, Boschi-PintoC, SteeleAD, DuqueJ, et al. (2011) 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 12: 136–141.

2. WHO (2009) Rotavirus vaccines: an update. Wkly Epidemiol Rec 84: 533–540.

3. Ruiz-PalaciosGM, Perez-SchaelI, VelazquezFR, AbateH, BreuerT, et al. (2006) Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354: 11–22.

4. VesikariT, MatsonDO, DennehyP, Van DammeP, SantoshamM, et al. (2006) Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354: 23–33.

5. ArmahGE, SowSO, BreimanRF, DallasMJ, TapiaMD, et al. (2010) Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 376: 606–614.

6. ZamanK, DangDA, VictorJC, ShinS, YunusM, et al. (2010) Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 376: 615–623.

7. MurphyTV, GargiulloPM, MassoudiMS, NelsonDB, JumaanAO, et al. (2001) Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 344: 564–572.

8. ButteryJP, DanchinMH, LeeKJ, CarlinJB, McIntyrePB, et al. (2011) Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 29: 3061–3066.

9. PatelMM, Lopez-ColladaVR, BulhoesMM, De OliveiraLH, Bautista MarquezA, et al. (2011) Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 364: 2283–2292.

10. PatelMM, HaberP, BaggsJ, ZuberP, BinesJE, et al. (2009) Intussusception and rotavirus vaccination: a review of the available evidence. Expert Rev Vaccines 8: 1555–1564.

11. GargiulloPM, MurphyTV, DavisRL (2006) Is there a safe age for vaccinating infants with tetravalent rhesus-human reassortant rotavirus vaccine? J Infect Dis 194: 1793–1794; author reply 1794–1795.

12. RothmanKJ, Young-XuY, ArellanoF (2006) Age dependence of the relation between reassortant rotavirus vaccine (RotaShield) and intussusception. J Infect Dis 193: 898; author reply 898–899.

13. World Health Organization (WHO). Global and national estimates of deaths under age five attributable to rotavirus infection: 2004 (as of 31 March 2006). Available: http://www.who.int/immunization_monitoring/burden/rotavirus_estimates/en/. Accessed 16 June 2008.

14. ClarkA, SandersonC (2009) Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data. Lancet 373: 1543–1549.

15. PatelMM, ClarkAD, GlassRI, GreenbergH, TateJ, et al. (2009) Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception. Vaccine 27: 2916–2922.

16. do CarmoGM, YenC, CortesJ, SiqueiraAA, de OliveiraWK, et al. (2011) Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med 8: e1001024 doi:10.1371/journal.pmed.1001024.

17. RichardsonV, Hernandez-PichardoJ, Quintanar-SolaresM, Esparza-AguilarM, JohnsonB, et al. (2010) Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 362: 299–305.

18. ShuiIM, BaggsJ, PatelM, ParasharU, RettM, et al. (2012) Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. JAMA 307: 598–604.

19. Sanderson C, Clark A, Taylor D, Bolanos B, Fine P (2012) Global review of rotavirus morbidity and mortality data by age and region. Paper for the Initiative for Vaccine Research, World Health Organization, Geneva. Available:http://www.who.int/immunization/sage/meetings/2012/april/Sanderson_et_al_SAGE_April_rotavirus.pdf. Accessed 12 April 2012.

20. AkmatovMK, MikolajczykRT (2011) Timeliness of childhood vaccinations in 31 low and middle-income countries. J Epidemiol Community Health 66: e14.

21. WHO (2003) List of Member States by.WHO region and mortality stratum. Available: http://www.who.int/whr/2003/en/member_states_182-184_en.pdf. Accessed 12 March 2012.

22. DHS (ENDES) (2000) Programa DHS/Macro International Inc. Available: http://www.measuredhs.com. Accessed 16 January 2012.

23. UNICEF (2004) Multiple indicator cluster survey (MICS). Available: http://www.unicef.org/statistics/index_24302.html. Accessed 31 January 2012.

24. WHO-UNICEF (2012) WHO-UNICEF estimates of DTP1 coverage. Available: http://apps.who.int/immunization_monitoring/en/globalsummary/timeseries/tswucoveragedtp1.htm. Accessed 31 January 2012].

25. PatelM, PedreiraC, De OliveiraLH, TateJ, OrozcoM, et al. (2009) Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 301: 2243–2251.

26. LinharesAC, VelazquezFR, Perez-SchaelI, Saez-LlorensX, AbateH, et al. (2008) Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 371: 1181–1189.

27. de PalmaO, CruzL, RamosH, de BairesA, VillatoroN, et al. (2010) Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ 340: c2825.

28. MadhiSA, CunliffeNA, SteeleD, WitteD, KirstenM, et al. (2010) Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 362: 289–298.

29. BreimanRF, ZamanK, ArmahG, SowSO, DangDA, et al. (2012) Ad hoc analyses of health outcomes from the 5 sites participating in the africa and asia clinical efficacy trials of oral pentavalent rotavirus vaccine. Vaccine 30 Suppl 1: A24–A29.

30. LanzieriTM, LinharesAC, CostaI, KolheDA, CunhaMH, et al. (2011) Impact of rotavirus vaccination on childhood deaths from diarrhea in Brazil. Int J Infect Dis 15: e206–210.

31. VelazquezFR, ColindresRE, GrajalesC, HernandezMT, MercadilloMG, et al. (2012) Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr Infect Dis J 31: 736–744.

32. EscolanoS, FarringtonCP, HillC, Tubert-BitterP (2011) Intussusception after rotavirus vaccination–spontaneous reports. N Engl J Med 365: 2139.

33. WoolfB (1955) On estimating the relation between blood group and disease. Ann Hum Genet 19: 251–253.

34. Abate H, Linhares AC, Venegas G, Vergara RF, Lopez P, et al.. A multi-center study of intussusception in Latin America: first year results [abstract]. Presented at: ICP; 15–20 August 2004; Cancun, Mexico.

35. BuettcherM, BaerG, BonhoefferJ, SchaadUB, HeiningerU (2007) Three-year surveillance of intussusception in children in Switzerland. Pediatrics 120: 473–480.

36. ChenYE, BeasleyS, GrimwoodK (2005) Intussusception and rotavirus associated hospitalisation in New Zealand. Arch Dis Child 90: 1077–1081.

37. FischerTK, BihrmannK, PerchM, KochA, WohlfahrtJ, et al. (2004) Intussusception in early childhood: a cohort study of 1.7 million children. Pediatrics 114: 782–785.

38. GayN, RamsayM, WaightP (1999) Rotavirus vaccination and intussusception. Lancet 354: 956.

39. HoWL, YangTW, ChiWC, ChangHJ, HuangLM, et al. (2005) Intussusception in Taiwanese children: analysis of incidence, length of hospitalization and hospital costs in different age groups. J Formos Med Assoc 104: 398–401.

40. JusticeF, CarlinJ, BinesJ (2005) Changing epidemiology of intussusception in Australia. J Paediatr Child Health 41: 475–478.

41. NelsonEA, TamJS, GlassRI, ParasharUD, FokTF (2002) Incidence of rotavirus diarrhea and intussusception in Hong Kong using standardized hospital discharge data. Pediatr Infect Dis J 21: 701–703.

42. O'RyanM, LuceroY, PenaA, ValenzuelaMT (2003) Two year review of intestinal intussusception in six large public hospitals of Santiago, Chile. Pediatr Infect Dis J 22: 717–721.

43. Perez-SchaelI, EscalonaM, SalinasB, MateranM, PerezME, et al. (2003) Intussusception-associated hospitalization among Venezuelan infants during 1998 through 2001: anticipating rotavirus vaccines. Pediatr Infect Dis J 22: 234–239.

44. Saez-LlorensX, GuevaraJN (2004) Intussusception and rotavirus vaccines: what is the background risk? Pediatr Infect Dis J 23: 363–365.

45. TateJE, SimonsenL, ViboudC, SteinerC, PatelMM, et al. (2008) Trends in intussusception hospitalizations among US infants, 1993–2004: implications for monitoring the safety of the new rotavirus vaccination program. Pediatrics 121: e1125–1132.

46. MooreSW, KirstenM, MullerEW, NumanogluA, ChitnisM, et al. (2010) Retrospective surveillance of intussusception in South Africa, 1998–2003. J Infect Dis 202 Suppl: S156–161.

47. LatipovR, KhudoyorovR, FlemE (2011) Childhood intussusception in Uzbekistan: analysis of retrospective surveillance data. BMC Pediatr 11: 22.

48. KohlLJ, StrengA, GroteV, KoletzkoS, LieseJG (2010) Intussusception-associated hospitalisations in southern Germany. Eur J Pediatr 169: 1487–1493.

49. ChenSC, WangJD, HsuHY, LeongMM, TokTS, et al. (2010) Epidemiology of childhood intussusception and determinants of recurrence and operation: analysis of national health insurance data between 1998 and 2007 in Taiwan. Pediatr Neonatol 51: 285–291.

50. BissantzN, JenkeAC, TrampischM, Klaassen-MielkeR, BissantzK, et al. (2011) Hospital-based, prospective, multicentre surveillance to determine the incidence of intussusception in children aged below 15 years in Germany. BMC Gastroenterol 11: 26.

51. BahlR, SaxenaM, BhandariN, TanejaS, MathurM, et al. (2009) Population-based incidence of intussusception and a case-control study to examine the association of intussusception with natural rotavirus infection among indian children. J Infect Dis 200 Suppl 1: S277–281.

52. BinesJE, PatelM, ParasharU (2009) Assessment of postlicensure safety of rotavirus vaccines, with emphasis on intussusception. J Infect Dis 200 Suppl 1: S282–290.

53. SteeleAD, PatelM, CunliffeN, BreseeJ, ParasharU (2012) Retrospective review of intussusception in 9 African countries. Vaccine 30: Suppl 1: A185–A189.

54. PatelMM, SteeleD, GentschJR, WeckerJ, GlassRI, et al. (2011) Real-world impact of rotavirus vaccination. Pediatr Infect Dis J 30: S1–S5.

55. PatelMM, GlassR, DesaiR, TateJE, ParasharUD (2012) Fulfilling the promise of rotavirus vaccines: how far have we come since licensure? Lancet Infect Dis 12: 561–570.

56. YenC, Armero GuardadoJA, AlbertoP, Rodriguez AraujoDS, MenaC, et al. (2011) Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. Pediatr Infect Dis J 30: S6–S10.

57. FieldEJ, VallyH, GrimwoodK, LambertSB (2010) Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in australia. Pediatrics 126: e506–512.

58. CortesJE, de OliveiraLH, PatelMM, ParasharU, CorteseM (2011) Reduction of diarrhea-associated hospitalizations among children aged <5 years in Panama following the introduction of rotavirus vaccine. Pediatr Infect Dis J 30: S16–S20.

59. BraeckmanT, Van HerckK, RaesM, VergisonA, SabbeM, et al. (2011) Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis J 30: S21–S24.

60. AnhDD, CarlosCC, ThiemDV, HutagalungY, GatchalianS, et al. (2011) Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006–2007. Vaccine 29: 2029–2036.

61. BallLK, EvansG, BostromA (1998) Risky business: challenges in vaccine risk communication. Pediatrics 101: 453–458.

62. BauchCT, EarnDJ (2004) Vaccination and the theory of games. Proc Natl Acad Sci U S A 101: 13391–13394.

63. ConnollyT, RebJ (2003) Omission bias in vaccination decisions: Where's the “omission”? Where's the “bias”? Organ Behav Hum Dec 91: 186–202.

64. WeijerC (2000) The future of research into rotavirus vaccine. BMJ 321: 525–526.

65. Available: http://www.cdc.gov/nchs/nis.htm. Accessed 3 January 2012.

66. WHO (2012) Meeting of the strategic advisory group of experts on immunization, April 2012–conclusions and recommendations. Wkly Epidemiol Rec 87: 212–213.